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Abstract Genomic sequencing has implicated large numbers of genes and de novo mutations as
potential disease risk factors. A high throughput in vivo model system is needed to validate gene
associations with pathology. We developed a Drosophila-based functional system to screen
candidate disease genes identified from Congenital Heart Disease (CHD) patients. 134 genes were
tested in the Drosophila heart using RNAi-based gene silencing. Quantitative analyses of multiple
cardiac phenotypes demonstrated essential structural, functional, and developmental roles for
more than 70 genes, including a subgroup encoding histone H3K4 modifying proteins. We also
demonstrated the use of Drosophila to evaluate cardiac phenotypes resulting from specific,
patient-derived alleles of candidate disease genes. We describe the first high throughput in vivo
validation system to screen candidate disease genes identified from patients. This approach has
the potential to facilitate development of precision medicine approaches for CHD and other
diseases associated with genetic factors.
DOI: 10.7554/eLife.22617.001
Introduction
A major problem confronting large-scale genomic sequencing studies of disease patients is to iden-
tify those genetic variants that actually represent disease-causing mutations. This is particularly true
for candidate genes that have not previously been evaluated in an experimental model system for
involvement in disease-relevant biological processes. Functional gene validation systems in model
organisms are therefore essential. While a definitive assignment of disease association should be
established through the analysis of mutant gene phenotypes in a mammalian model, this approach
is not practical for rapid high-throughput initial screening of large numbers of candidate genes. Dro-
sophila, by contrast, possesses the attributes of a simple animal model system that make it ideally
suited for this role (Bier, 2005; Chien et al., 2002).
Use of Drosophila as a model to elucidate molecular disease mechanisms is well established and
amply documented (Cagan, 2011; Na et al., 2015; Zhang et al., 2013; Diop and Bodmer, 2015;
Bier and Bodmer, 2004; Owusu-Ansah and Perrimon, 2014). It has been established that 75% of
human disease associated genes are represented in the fly genome by functional homologs
(Reiter et al., 2001). Although it is difficult to directly link Drosophila developmental defects to
patient symptoms, the Drosophila system can serve as a testing platform for gene function in devel-
opment, which can be used to test disease association for a large number of candidate genes identi-
fied from patient genomic sequencing.
Congenital heart disease (CHD) affects 0.8% of live births (Hoffman, 1990, 2002; Reller et al.,
2008). Genetic factors are strongly implicated in CHD pathogenesis, but the great majority of genes
(accounting for an estimated 75% of cases) remain unidentified (Gelb et al., 2013). Drosophila has
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served as a model to study genes related to CHD for over 20 years, based on the evolutionarily con-
served genetic basis of heart development (Bier and Bodmer, 2004; Olson, 2006; Yi et al., 2006).
The Drosophila heart (Figure 1A) is a rhythmically beating linear tube composed of parallel rows of
fused contractile cardiac cells, flanked by adherent pericardial cells (Vogler and Bodmer, 2015).
The heart functions to maintain circulation of hemolymph (insect ‘blood’) throughout the body cav-
ity. In a typical beating cycle, hemolymph enters the posteriorly-located heart chamber in the abdo-
men and is pumped anteriorly through the aorta towards the head and brain. Although structurally
of relatively low complexity, Drosophila and human heart development are both largely directed by
the same highly conserved regulatory networks (Vogler and Bodmer, 2015). To demonstrate that
the fly is the ideal in vivo animal model for cost-effective, rapidly informative, and efficient screening
of candidate disease genes, we have developed a Drosophila validation system to screen candidate
genes identified in a large-scale genomic sequencing study of congenital heart disease patients.
In 2013 the Pediatric Cardiac Genomics Consortium (PCGC) published a large-scale sequence
analysis of sporadically occurring CHD cases (Zaidi et al., 2013), providing an opportunity to con-
duct systematic model system based experimental studies into the genetic basis of CHD, informed
from the outset by clinical data. Such studies will ultimately facilitate the development of diagnostic,
therapeutic, and preventive approaches, and precision medicine interventions (Ashley, 2015) for
CHD. The initial report (Zaidi et al., 2013) of 249 protein-altering de novo mutations from 362
severe cases of CHD identified 223 candidate disease genes involved in diverse biochemical path-
ways, with 26 genes selected as particular genes-of-interest based upon bioinformatics criteria
(Zaidi et al., 2013). We used Drosophila developmental genetics to quantitatively evaluate the phe-
notypes associated with heart-specific RNAi mediated gene silencing of fly homologs of mutated
candidate disease genes. 174 genes (78%) had clear fly homologs, consistent with the published esti-
mate of 75% conservation of disease gene homologs (Reiter et al., 2001). Interestingly, the ‘top 26’
genes identified by the PCGC study (Zaidi et al., 2013) all have conserved Drosophila homologs.
Some of these genes were previously identified as having roles in Drosophila heart development, in
eLife digest Around one in 100 children are born with heart defects caused by congenital heart
disease. Studying the genetic sequences of people with congenital heart disease has revealed many
genes that may play a role in causing the condition, but few of these findings have been confirmed
experimentally in animal model systems.
The fruit fly species Drosophila melanogaster is often used in genetic studies because it is a
relatively simple organism. The insights gained from studying flies are often valuable for determining
the direction of subsequent investigations in more complex animals – such as humans – that involve
experiments that are more costly and less efficient.
Zhu, Fu et al. have now used fruit flies to investigate the effects of 134 genes that have been
suggested to contribute to congenital heart disease. The investigation used a method that rapidly
allowed the activity of specific genes to be altered in the flies. The effects that these alterations had
on many aspects of heart development, structure and activity were then measured. Of all the genes
tested, 70 caused heart defects in the flies. Several of these genes help to modify the structure of
proteins called histones; these modifications play important roles in heart cell formation and growth.
Further tests showed that the effects of specific genetic errors that had been identified in people
with congenital heart disease could be reliably reproduced in the flies. This may allow individual
cases of congenital heart disease to be replicated and studied closely in the lab, helping to create
treatments that are personalised to each patient.
Studying congenital heart disease in flies provides a fast and simple first step in understanding
the roles that different genes play in the disease. Moving forward, precise gene editing techniques
could be used to generate flies to examine the role of each of the genetic mutations that occur in
individual patients. Ultimately, when gene editing techniques are ready to be used in humans, this
could lead to cures for congenital heart disease at the DNA level, so that these mutations won’t be
passed on to the next generation.
DOI: 10.7554/eLife.22617.002
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Figure 1. Drosophila adult heart structure and tissue visualization, evaluation of 1X vs. 4X Hand enhancer constructs driving heart specific silencing of
gene expression. (A) Drosophila heart structure and visualization. Left: the adult heart is depicted schematically in green. Supporting lateral alary
muscles are depicted in red. Middle: fluorescence microscopy of dissected heart tissue spanning abdominal segments A2–A5. Myocardial actin
filaments (cardiac myofibers) were visualized by Phalloidin staining (red), which also stained somatic muscle fibers in segments A2, A3, and A4 and alary
muscle fibers in A5. GFP (green) labels cardiomyocytes and pericardial nephrocytes. Expression of a nuclear-localized GFP transgene was controlled by
the cardioblast specific Hand gene enhancer element. Scale bar = 100 m. Right: higher magnification of segment A4 heart tissue. Scale bar = 50 m. In
this example, dissection and preparation for microscopy involved removal of a layer of longitudinal muscle, which resulted in the loss of some
cardiomyocytes and pericardial nephrocytes. In situ, the heart tube is composed of parallel, symmetrical rows of cardiomyocytes (small nuclei), flanked
by pericardial nephrocytes (large nuclei). (B) The 4XHand enhancer promotes significantly greater Gal4 mRNA production than the single Hand
enhancer. The Gal4 mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (*) was defined as p<0.05. w1118 was
used as a negative control since it does not express any Gal4. (C) Compared to the single Hand enhancer, 4XHand induced significantly greater
knockdown of CG8184 (the homolog of human HUWE1) mRNA when driving expression of the CG8184-IR RNAi silencing transgene. The CG8184
mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (*) was defined as p<0.05. (D) Compared to the single
Hand enhancer, 4XHand induced significantly greater knockdown of Lid (the homolog of human KDM5A and KDM5B) mRNA when driving expression
of the Lid-IR RNAi silencing transgene. The Lid mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (*) was
defined as p<0.05. In C and D, Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and w1118, which has one copy of 4xHand-
Gal4 but does not carry a UAS-RNAi silencing construct.
DOI: 10.7554/eLife.22617.003
The following figure supplement is available for figure 1:
Figure supplement 1. 4XHand-Gal4 efficiently silences cardiac gene expression.
DOI: 10.7554/eLife.22617.004
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the context of a global in vivo RNAi screen for candidate fly heart genes. (Neely et al., 2010) The
current study used a stronger heart-specific driver to validate candidate CHD genes.
We developed a highly efficient cardiac-targeted gene silencing approach in flies, and used this
to examine effects on heart structure and function for fly homologs of 134 candidate disease genes
published by the PCGC. We employed a quantitative phenotypic screening protocol that evaluated
developmental lethality (pre-adult mortality), heart structure (Figure 1A; including morphology, car-
diac myofibrillar density, cardiac collagen deposition, and cardioblast cell number) and adult longev-
ity. We found that 52% of the tested fly homologs are required for cardiac development and
function in flies. We also developed a gene replacement testing strategy involving simultaneous
heart-specific silencing of an endogenous fly gene homolog and expression of either wild type or
patient-derived mutant alleles of the candidate human disease gene.
Results
To achieve a highly efficient heart-specific gene knock down, we generated a strong cardiac cell
Gal4 driver featuring 4 tandem repeats of the Drosophila Hand gene cardiac enhancer (Han and
Olson, 2005). We compared the levels of Gal4 RNA in heart tissues of transgenic flies carrying the
new 4XHand-Gal4 driver construct versus flies carrying the original, established Hand-Gal4 driver
(featuring a single Hand enhancer element). As anticipated, 4XHand promoted significantly higher
heart cell expression of Gal4 mRNA (Figure 1B). We then compared the Hand-Gal4 and 4XHand-
Gal4 drivers together with UAS-Gene-IR RNAi based silencing constructs (Ni et al., 2008, 2011) for
gene knock down efficiency when used to silence expression (i.e. lower heart cell RNA levels) of Dro-
sophila genes CG8184 (Figure 1C) and Lid (Figure 1D). Consistent with the higher Gal4 expression,
4XHand was significantly more effective at silencing target gene expression through RNAi. To fur-
ther confirm the utility of 4XHand-Gal4 for screening purposes, we comparatively evaluated the
Hand-Gal4 and 4XHand-Gal4 constructs driving heart-specific expression of UAS-RNAi transgenes
targeting eight Drosophila genes for developmental lethal (death at pre-adult stage) effects. The
Hand enhancer is active during development from embryonic stages, and we reasoned that Hand
enhancer-driven silencing of genes known to be essential for heart development would cause devel-
opmental lethality. For this assay, male and female flies of the appropriate genotypes were crossed
to produce progeny carrying the indicated UAS-gene silencing (i.e. RNAi) interfering RNA (IR) con-
struct, the expression of which was driven by Hand-Gal4 or 4XHand-Gal4. Progeny embryos were
collected and allowed to develop under standard conditions. The results were quantitatively
expressed as a Mortality Index (MI), the percentage of flies that died before adult emergence from
the pupa stage. We found that for all eight tested genes, significant developmental lethal effects of
heart-specific gene silencing were only observed in flies carrying a 4XHand-Gal4 driver (Figure 1—
figure supplement 1).
We combined the new 4XHand-Gal4 driver with available fly lines carrying UAS-Gene-IR RNAi
based silencing constructs to evaluate for heart specific essential function (i.e. MI) the homologs of
all genes from the PCGC study for which multiple independent UAS-RNAi lines are available (134
total genes, Supplementary file 1). We extracted the data for the PCGC top 26 genes, identified as
most-promising candidate disease genes on the basis of multiple bioinformatics-based criteria
(Figure 2A). We reasoned that if these criteria alone were truly informative, the majority of these
genes would yield higher MI scores, overall, than observed among all 134 tested genes representing
the PCGC total list. As shown in Figure 2 we observed MI values ranging across a spectrum span-
ning Normal (6%, equivalent to nonbiased control genes), Low (7–30%), Medium (31–60%), to High
(61–100%). Importantly, we found that the distribution of MI values across all ranges was not signifi-
cantly different for the top 26 genes compared to the entire cohort of 134 candidate genes tested
(Figure 2A). Thus, selection of candidate CHD genes on the basis of bioinformatics criteria alone did
not enrich for genes inducing more severe developmental mortality phenotypes (indicative of more
genes with essential roles in either heart development, tissue maintenance, or function). This obser-
vation emphasizes the importance of screening and selecting most-promising candidate genes on
the basis of functional assays. To determine if the set of 134 candidate genes in itself can be demon-
strated to be enriched for heart-essential genes, we examined previously obtained data from a
screen of approximately 800 Drosophila genes silenced using the 4XHand-Gal4; UAS-RNAi system.
These genes were randomly chosen to screen for effects on pericardial nephrocyte function
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(cardioblast lineage cells in which the Hand enhancer is active), so they are unbiased with respect to
essential heart roles. We found that only 6% of these genes showed any level of developmental
lethality when silenced (i.e. 94% normal). Thus, the PCGC genomic association study, though not
gene selection based upon bioinformatics criteria, did enrich significantly for heart-essential genes
as assayed in Drosophila. That such a small number of unbiased genes conferred a phenotype of
silencing-induced developmental lethality also suggests that overexpression of 4xHand-Gal4 itself
did not sensitize flies to RNAi mediated knockdown effects.
Figure 2. Top 26 candidate CHD genes and developmental lethality induced by heart specific RNAi-based silencing of Drosophila gene homologs.
(A) 26 de novo mutated genes from CHD study participants selected as being of particular interest (Zaidi et al., 2013) based upon sequence quality,
mutation type, the expression level of the mouse homolog during heart development on embryonic day 14.5, and previously reported involvement in
CHD or heart development. The 26 corresponding Drosophila homologs are shown with protein function (Flybase), and Mortality Rate (Mortality Index).
(B–D) The proportions of Drosophila gene homologs that, when silenced by cardiac cell specific RNAi expression, induce developmental lethality at
normal/background levels (blue); low levels (green); medium levels (orange); high levels (red) based on Mortality Index values. The Mortality Index is
determined by crossing homozygous UAS-RNAi transgenic flies with flies bearing a 4XHand-Gal4 ‘driver’ (four repeats of the cardioblast cell-specific
Hand enhancer element 5’ of Gal4) balanced over CyO. Progeny flies that emerge as adults with curly wings (CyO, no transgene expression) vs. straight
wings (expressing 4XHand-Gal4 driven UAS-RNAi transgene in cardioblasts) are recorded and the developmental mortality attributable to RNAi heart
expression (Mortality Index) is calculated as (Curly – Straight) / Curly X 100. Divergence from 1:1 ratio (Normal, blue)  7% was considered a lethal
phenotype. A Normal range of divergence from a 1:1 ratio of <6% based on analysis of 400 progeny from control crosses. Varying degrees of
phenotype severity were observed (Low = 7–30%, green; Medium = 31–60%, orange; High = 61–100%, red). (B) Left: chart (PCGC top 26) shows
proportions of RNAi silencing effects on lethality for Drosophila homologs of 26 genes identified as being of particular interest based exclusively on
bioinformatics-based criteria. Right: chart (PCGC total list) shows the results of 134 fly homologs of all de novo mutated genes (with available RNAi
silencing lines) identified in pediatric CHD study participants (Zaidi et al., 2013) (Supplementary file 1). (C) Comparison of silencing-induced lethality
for Drosophila homologs of 134 candidate CHD-associated genes as a function of high (HHE) versus low (LHE) levels of expression of murine homologs
in embryonic mouse heart. (D) Comparison of silencing-induced lethality for Drosophila homologs of 134 candidate CHD-associated genes as a
function of fly-to-human gene conservation (High Conservation, score 6 to 10; Low Conservation, score 2 to 5).
DOI: 10.7554/eLife.22617.005
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We also stratified and compared MI values we obtained for all of the 134 Drosophila genes as
functions of expression level of murine homologs during mouse embryonic heart development, as
reported in the PCGC study (and one basis for selection of top 26 genes) (Zaidi et al., 2013). As
shown in Figure 2C, high heart expression (HHE) during development did not correlate with greater
severity of developmental lethality associated with gene silencing in Drosophila heart. Contrary to
expectation, low heart expression (LHE) of murine homologs was associated with relatively higher
severity of Drosophila gene silencing. These observations again emphasize the importance of apply-
ing functional screening assays to the results of genomic sequencing studies. We noted nevertheless
that the top 26 genes all have Drosophila homologs, including 22 that are highly conserved. When
mortality was assayed as a function of degree of fly-human conservation among all 134 tested genes
(Figure 2D) we did observe greater mortality among highly conserved genes compared to less con-
served genes. Not surprisingly, phylogenetic conservation indeed correlated positively with MI, a
result that further supports using Drosophila as a model for functional evaluation of candidate genes
for disease association.
In order to confirm that RNAi based phenotypes were indeed associated with target gene mRNA
reduction, we measured RNA levels in heart tissue from flies expressing silencing constructs target-
ing six different genes from the top 26 group. These genes were chosen for analysis because they
represent a range of different cellular functions, and include three genes for which silencing did not
induce developmental lethality. MI values for the six genes ranged from normal to 43%. As shown in
Figure 3, heart RNA levels of target genes were all significantly reduced. Furthermore, we tested
developmental lethal phenotypes for all top 26 genes using two or more independent RNAi silenc-
ing fly lines for each gene, and obtained consistent MI results in all cases (data not shown).
Eight of the top 26 gene homologs encode products involved in histone H3K4 and H3K27 methyl-
ation (Figures 2A and 4). Epigenetic activating (H3K4me) and inactivating (H3K27me) marks are
associated with selective activation of promoters and enhancers, and chromatin marks are associated
with specification and differentiation of cardiac cells (Wamstad et al., 2012), murine heart develop-
ment (He et al., 2012; Delgado-Olguı́n et al., 2012), and cardiac pathogenesis (Kaneda et al.,
2009; Zhang and Liu, 2015). Two additional top 26 genes (SUV420H1 and HUWE1) also encode
conserved histone modifying proteins. Thus 42% of the top candidate genes from the PCGC study
are involved in histone modification pathways, and all but one are highly conserved. Because chro-
matin modification pathway associated genes represent the major functional class among the ‘top
26’, we chose to examine in more detail the roles of these genes in Drosophila heart morphogenesis
and function.
We analyzed heart phenotypes resulting from cardiac-specific silencing of the eight genes
involved in H3K4 and H3K27 methylation (Figure 4). Silencing kismet yielded an adult heart pheno-
type in which the heart tube was severely affected (Figure 4B) with very low cardiac myofibrillar den-
sity (Figure 4C), elevated Pericardin (collagen) deposition (Figure 4D), and reduced numbers of
cardioblasts (Figure 4E). Adult fly longevity was significantly affected, with approximately 50% of
flies dead by day 25 (Figure 4F). During development, kismet silencing caused 54% mortality
(Figure 2A). In larvae, cardiac myofibrillar density was reduced with pronounced heart tube filament
disruption (Figure 4G,H), and Pericardin over-expression with disorganized ECM deposition
(Figure 4G,I). Trx-silenced adult flies lacked cardiac actin and heart tube (Figure 4B,C), exhibited
severely reduced Pericardin (Figure 4D), almost no cardioblast cells (Figure 4E), and all were dead
at day 25 after emergence, compared to 20% mortality among control flies (Figure 4F). Trx silencing
caused 35% developmental lethality (Figure 2A). In larvae, knock down of trx induced abnormal
heart tube structure (Figure 4G) with reduced cardiac myofibrillar density (Figure 4G,H) and
reduced Pericardin (Figure 4G,I). Silencing of wds caused complete developmental lethality
(Figure 2A) and a dramatic larva heart phenotype (Figure 4G) featuring abnormal cardiac actin
organization and fiber density (Figure 4H), and extremely high levels of Pericardin (Figure 4G,I).
Taken together, these results strongly suggest that H3K4 methylation is critical for normal heart
development and function, a conclusion supported by the observation that knockdown of the H3K4
de-methylase Lid had no phenotypic consequences (Figure 4C–F,H,I; Figure 4—figure supplement
1). Similarly, silencing of SMOX (involved in H3K27 de-methylation) resulted in minimal developmen-
tal mortality (MI 7%, Figure 2A) but normal cardiac myofibrillar density and Pericardin levels in larvae
(Figure 4H,I). The adult heart phenotype was essentially normal, as was adult mortality at day 25
(Figure 4).
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Ubiquitination of H2BK120 (Figure 4A) is required for H3K4 methylation, and we observed that
silencing of the UbcD6 gene resulted in 84% developmental mortality (Figure 2A) and reduced adult
longevity (Figure 4F; Figure 4—figure supplement 1). The adult heart was severely affected (Fig-
ure 4—figure supplement 1) with greatly reduced cardiac myofibrillar density (Figure 4C), elevated
Pericardin (Figure 4D), and reduced cardioblast cell numbers (Figure 4E). Silencing of Bre1 and
Scny also caused developmental mortality and cardiac myofibrillar density was somewhat reduced in
larvae and adults (Figure 4C,H). Pericardin levels, cardioblast cell numbers, and adult mortality at
day 25 were essentially normal (Figure 4D,E,F,I). By contrast, H3K4 de-methylation did not appear
critical as evidenced by the essentially normal heart phenotype, normal MI, and normal adult longev-
ity observed upon Lid silencing. (Figure 4 and Figure 4—figure supplement 1). These results fur-
ther demonstrate the utility of the Drosophila system to functionally test large-scale clinical
genomics data and gain insights into fundamental pathways contributing to disease pathogenesis.
We used dye angiography to measure effects on heart function of cardiac-specific silencing of the
eight genes involved in H3K4 and H3K27 methylation (Figure 5). Briefly, fluorescent dye was
injected into the posterior abdomen of pharate (pre-eclosion) adult flies, where it entered the heart
chamber and was pumped anteriorly. Dye accumulation in the head over a 30 s time interval pro-
vided a measurement of cardiac efficiency (Figure 5A,B) (Drechsler et al., 2013). We observed that
in normal control flies fluorescent dye is readily detectable in the head within 15 s of injection, and
Figure 3. Target gene mRNA levels in adult fly heart tissues. (A) Drosophila Cul3 homolog of human CUL3 encoding ubiquitin ligase (Mortality Index
43%). (B) Drosophila Scny homolog of human USP44 encoding ubiquitin protease (Mortality Index 25%). (C) Drosophila Bre1homolog of human RNF20
encoding ubiquitin ligase E3 (Mortality Index 13%). (D) Drosophila Rab10 homolog of human RAB10 encoding GTPase (Mortality Index normal). (E)
Drosophila Med20 homolog of human MED20 (Mortality Index normal). (F) Drosophila CG15445 homolog of human NUB1 (Mortality Index normal).
mRNA levels in dissected adult hearts were determined by qRT-PCR. Statistical significance (*) was defined as p<0.05. Control flies were the progeny of
a cross between homozygous 4XHand-Gal4 and w1118, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.
DOI: 10.7554/eLife.22617.006
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Figure 4. Genes involved in H3K4 and H3K27 methylation, mutated in CHD patients, affect heart structure, developmental mortality, and adult survival.
(A) Depiction of nucleosome showing H3K4 and H3K27 methylation, and ubiquitination of H2BK120 (required for H3K4 methylation). Drosophila
homologs involved in the production, removal, or interpretation of modifications are shown (human genes shown in red). (B) Adult heart phenotype
induced by cardioblast-specific expression (driven by 4XHand-Gal4) of UAS-RNAi transgenes targeting Kismet and Trx. Cardiac actin (myofibers) was
Figure 4 continued on next page
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significantly accumulated by 30 s. By contrast, silencing of candidate CHD gene homologs involved
in the methylation of H3K4 and H3K27 profoundly impaired cardiac function (Figure 5B,C). Silencing
of Smox and Lid, however, did not measurably impair heart function as measured in this assay. These
observations indicate that H3K4 and H3K27 methylation, and not demethylation, is essential for
heart function, consistent with our findings with regard to cardiac tissue morphology and effects on
developmental lethality and adult longevity.
Gene silencing using available and well-established UAS-RNAi fly lines allows rapid and efficient
functional screening of large numbers of candidate genes. We also established an in vivo platform to
analyze the cardiac phenotypes of specific patient-derived alleles of candidate CHD genes in Dro-
sophila, employing a ‘gene replacement’ strategy. As a proof-of-concept, we tested the ability of a
wild type human WDR5 allele to rescue heart phenotypes induced by silencing of the endogenous
wds Drosophila homolog. Heart-specific silencing of wds caused 100% developmental lethality and
abnormal heart morphology in late larvae characterized by reduced cardiac myofibers and severe
over-deposition of Pericardin (Figure 6). We found that simultaneously overexpressing a wild type
human WDR5 allele reduced developmental lethality almost 7-fold, significantly restored cardiac
myofibrillar density, and reduced Pericardin levels essentially to normal (Figure 6). By contrast, when
the endogenous wds expression was ‘replaced’ by a CHD patient-derived WDR5-K7Q mutant allele,
developmental lethality remained quite elevated, cardiac myofibrillar density remained abnormally
low (relative both to Control and wild type WDR5 rescue), and Pericardin levels were lowered but
still significantly higher than both Control and wild type WDR5 rescue. These observations illustrate
the structure-function homologies between human and fly ‘heart genes’ that support use of Dro-
sophila for functional validation of candidate CHD genes. Moreover, they demonstrate that the
‘gene replacement’ strategy can be used to quantitatively assess phenotypes induced by patient-
specific alleles of candidate disease genes.
Discussion
Our results demonstrate the value of the Drosophila model system to functionally screen and vali-
date candidate disease genes identified through large scale sequencing efforts. The high-throughput
testing platform described here can extend gene association data to quantitative, in vivo morpho-
logical and functional criteria. On the basis of this screening, the most promising genes can justifi-
ably be advanced to more costly, time consuming, and technically challenging validation platforms
required to definitively identify and confirm disease-causing gene variants. Such advanced testing,
we presume, will encompass gene function analysis in a mammalian model system.
The advantages of functional screening using RNAi-based silencing lines are to some extent off-
set by certain limitations. From the outset, of human disease genes, approximately 25% are not rep-
resented by Drosophila homologs. False negatives may occur if RNAi expression does not
Figure 4 continued
visualized by Phalloidin staining. Hand-GFP expression (nuclear) labels cardioblast cells. Pericardin was immune-labeled. Dotted lines delineate
the heart tube outline. Red arrow points to remnant cardioblast cell in Trx-silenced heart. Scale bar = 50 m. (C) Quantitation of adult heart cardiac
myofibrillar density (as % of control; N = 10 for Control, N = 6 for indicated silenced gene). Statistical significance (*) was defined as p<0.05. Scale
bar = 50 m. (D) Quantitation of adult heart cardiac collagen (Pericardin) deposition (as % of control; N = 10 for Control, N = 6 indicated silenced gene).
Statistical significance (*) was defined as p<0.05. (E) Quantitation of adult heart cardioblast cell numbers (cardioblasts expressing nuclear GFP; N = 10
for Control, N = 10 for indicated silenced gene). Statistical significance (*) was defined as p<0.05. (F) Percentage of adult male flies dead at day 25
post-emergence (N = 50 flies per genotype). (G) Larva (third instar) heart phenotypes induced by cardioblast-specific expression (driven by 4XHand-
Gal4) of UAS-RNAi transgenes targeting Wds, Kismet, and Trx. Cardiac actin (myofibers) was visualized by Phalloidin staining. The pericardin was
immune-labeled. Dotted lines delineate heart tube outline. (H) Quantitation of larval heart cardiac myofibrillar density (as % of control; N = 10 for
Control, N = 6 for indicated silenced gene). Statistical significance (*) was defined as p<0.05. (I) Quantitation of larva heart cardiac collagen (Pericardin)
deposition (as % of control; N = 10 for Control, N = 6 for indicated silenced gene) Statistical significance (*) was defined as p<0.05. Control flies were
the progeny of a cross between homozygous 4XHand-Gal4 and w1118, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing
construct.
DOI: 10.7554/eLife.22617.007
The following figure supplement is available for figure 4:
Figure supplement 1. Genes involved in H3K4 and H3K27 methylation, mutated in CHD patients.
DOI: 10.7554/eLife.22617.008
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sufficiently reduce mRNA levels. However, we tested a number of RNAi lines by qRT-PCR and found
no examples of ineffective gene silencing. False negatives may also occur when missense mutations
produce gain-of-function (GOF) alleles, and we cannot accurately predict the degree to which this
could confound our analysis. This problem, we note, is mitigated to a degree by the fact that genes
altered by GOF mutations would in many instances normally encode proteins with cardiac cell func-
tions, and thus yield silencing induced phenotypes in our functional screening system. False positives
can arise from so-called ‘off target’ effects of a given RNAi targeting construct. We controlled
against misleading results from both RNAi silencing inefficiency and off target effects by employing
the latest-generation available RNAi lines, and testing multiple such lines for each of the top 26 can-
didate genes. This precaution against false negative and false positive results further limited the total
number of candidate genes we could screen to 134 (60% of the CHD candidate genes published by
Figure 5. Direct measurement of heart function. (A) The adult heart is depicted schematically in green. Supporting lateral alary muscles are depicted in
red. Fluorescent dye injected into the posterior body cavity (arrow) enters the heart tube lumen and is pumped anteriorly into the brain region. (B) Time
course of injected fluorescent dye entering the brain region (dotted outline). In normal control flies dye is easily detectable 15 s (s) after injection, and
the brain is highly fluorescent within 30 s. In flies expressing heart-specific Wds or Kismet gene targeting RNAi silencing constructs, by contrast, dye
does not reach the brain by 30 s after injection. Scale bar = 100 m. (C) Quantitative analysis of brain region fluorescence, relative to control fly levels, as
a function of heart-specific gene silencing. Experiments were performed in triplicate (3 independent dye injection experiments). Statistical significance
(*) was defined as p<0.05. Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and w1118, which has one copy of 4xHand-Gal4
but does not carry a UAS-RNAi silencing construct.
DOI: 10.7554/eLife.22617.009
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Figure 6. Wds silencing-induced lethality and heart phenotypes rescued by wild type human WDR5 but not by a
patient derived WDR5-K7Q mutant allele. (A) Developmental lethality (Mortality Index) for flies in which
endogenous Wds heart expression was silenced, and attempted rescue by either wild type WDR5 or mutant
WDR5-K7Q overexpression (OE). (B) Larva (third instar) heart phenotype induced by cardioblast-specific expression
Figure 6 continued on next page
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the PCGC). Nevertheless, our in vivo screening system rapidly and efficiently confirmed roles in heart
development, tissue maintenance, or cardiac function for 72 candidate genes.
Phenotypic analysis based on gene silencing, while effective for high throughput screening, repre-
sents a first step in validation and characterization of candidate mutations. We also demonstrated an
initial ‘gene replacement’ strategy that takes further advantage of the available resources and
sophisticated genetics of the Drosophila model system to quantitatively characterize the phenotype
induced by expression of a specific patient-derived mutant allele. This approach may prove highly
valuable as a testing platform for precision medicine based therapeutic drugs. Ultimately, the knowl-
edge that a specific mutation contributes to disease pathogenesis opens the door to the application
of precise gene-editing interventions, strategies for which are currently being developed based on
CRISPR/Cas-9 mediated genome editing (Long et al., 2016; Carroll et al., 2016; Long et al.,
2014). The high throughput candidate gene validation studies reported here represent the essential
first step in the functional confirmation, phenotypic characterization, and ultimate precision treat-
ment of disease-associated mutations.
Materials and methods
Fly stocks
Drosophila lines were obtained from the Bloomington Stock Center (Bloomington, IN; NIH
P40OD018537). Transgenes were overexpressed with the UAS-GAL4 system (Brand and Perrimon,
1993). To increase the penetrance of heart-specific UAS-RNAi mediated gene silencing we devel-
oped a powerful Gal4 driver incorporating four repeats of the Hand gene (Han et al., 2006)
enhancer. 4XHand-Gal4 was generated by tandem insertions of the original Hand cardiac-specific
enhancer (Han and Olson, 2005) in the pGal4 vector.
DNA cloning and generation of transgenic fly strains
The wild type WDR5 cDNA was obtained from OriGene, which encodes the 334 a.a. protein with
GenBank ID P61964. The WDR5-K7Q cDNA was generated by introducing the K7Q mutation into
the wild type WDR5 cDNA sequence using PCR. To generate UAS-WDR5 and UAS-WDR5-K7Q con-
structs, the above cDNAs were cloned into the pUASTattB vector and the transgenes were intro-
duced into a fixed chromosomal docking site by germ line transformation.
Dye angiography
Pharate (pre-eclosion) adult flies were carefully removed from pupa cases and affixed by double-
sided scotch tape to glass slides. A single injection of 100 nl of uranin solution (1 mg/ml in PBS) was
delivered into the abdomen using a Drummond Nanoject II auto-nanoliter injector with a glass capil-
lary. Dye accumulation in the fly head was monitored over a 3 min interval using a Zeiss ApoTome.2
microscope with a 5x Plan-Neofluar 0.16 air objective. Experiments were performed in triplicate (3
independent dye injection experiments). ImageJ software Version 1.49 was used for image process-
ing and quantification. Fluorescence intensity in the fly head was measured at times 0 (time of
Figure 6 continued
(driven by 4XHand-Gal4) of UAS-RNAi transgene targeting Wds, and attempted rescue by WDR5 or WDR5-K7Q
overexpression. Cardiac actin (myofibers) visualized by Phalloidin staining. Pericardin was immune-labeled. Dotted
lines delineate the heart tube outline. (C) Quantitation of larval heart cardiac myofibrillar density (as % of control;
N = 10 for Control, N = 6 for Wds-IR, Wds-IR+WDR5-OE, or Wds-IR+WDR5-K7Q-OE). Statistical significance (*)
was defined as p<0.05. For each strain, fiber density was significantly lower than control. Rescue by wild type
WDR5 significantly rescued fiber density, to levels significantly greater than achieved by the overexpression of the
WDR5-K7Q mutant allele. (D) Quantitation of larva heart cardiac collagen (Pericardin) deposition (as % of control;
N = 10 for Control, N = 6 for Wds-IR, Wds-IR+WDR5-OE, or Wds-IR+WDR5-K7Q-OE) Statistical significance (*)
was defined as p<0.05. Wild type WDR5-OE fully rescued up-regulated collagen deposition induced by Wds-IR.
Mutant WDR5-K7Q-OE partially rescued the Wds-IR phenotype, but collagen deposition levels remained
upregulated compared to the control. The control flies were the progeny of a cross between homozygous
4XHand-Gal4 and w1118, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.
DOI: 10.7554/eLife.22617.010
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injection) and 30 s post-injection. Increased fluorescence values represent fluorescence at t = 30 s
minus t = 0, and were expressed relative to head fluorescence of control flies not expressing an
RNAi targeting transgene.
qRT-PCR analysis
RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) from heart tissue dissected from
60 adult flies of the relevant genotype. RNA purity and concentration were determined using a
Nanodrop-1000 (Thermo Scientific, Wilmington, DE). Total RNA (1 mg) was reverse transcribed using
Superscript IV (Invitrogen). SYBR Green based real-time qPCR (Power Cyber Mastermix; Applied
Biosystems, Carlsbad, CA) was performed using a StepOne Plus (Applied Biosystems). Gene-specific
primer pairs were used. Quantitative values were determined using the 2-DDCT method (Livak and
Schmittgen, 2001), normalizing to Gapdh. Values are derived from three technical replicates of
qRT-PCR experiments from pooled RNA.
Fly imaging
Larvae and adult flies were dissected and fixed for 10 min in 4% paraformaldehyde in phosphate-
buffered saline (PBS). Alexa Fluor 555 Phalloidin was obtained from Thermo Fisher. Mouse anti-Peri-
cardin antibody (EC11) was used at 1:500 dilutions, followed by Cy3-conjugated secondary antibod-
ies (Jackson Lab). Confocal imaging was performed with a Zeiss ApoTome.2 microscope using a
20 Plan-Apochromat 0.8 N.A. air objective. For quantitative comparisons of intensities, common
settings were chosen to avoid oversaturation. ImageJ Software Version 1.49 was used for image
processing. For quantitative comparisons of cardiac myofibrillar density, cardioblast cell numbers,
and Pericardin deposition we analyzed six to ten control flies and six to ten flies of each experimen-
tal genotype. These features were quantitatively assessed in the same area of the same segment in
each fly. Cardiac myofiber levels of Z-stack projections were carefully selected for analysis, avoiding
the ventral muscle layer underlying the heart tube. Sample size determinations were based upon
extensive previous experience in analyzing fly heart morphology.
Survival assay
Within 24 hr of egg laying Drosophila larvae were transferred from 25˚C to 29˚C to boost UAS-trans-
gene expression. Adult male flies were maintained at 29˚C in groups of 15 or fewer; 50 flies in total
were assayed per genotype.
Statistical analysis
Statistical tests were performed using PAST.exe software (http://folk.uio.no/ohammer/past/index.
html) unless otherwise noted. Sample errors are given as standard error of the mean (s.e.m). Data
were first tested for normality by using the Shapiro-Wilk test (a = 0.05). Normally distributed data
were analyzed either by Student’s t-test (two groups) and Bonferroni comparison to adjust p value
or by a one-way analysis of variance followed by a Tukey-Kramer post-test for comparing multiple
groups. Non-normal distributed data were analyzed by either a Mann-Whitney test (two groups) and
Bonferroni comparison to adjust the p value or a Kruskal-Wallis H-test followed by a Dunn’s test for
comparisons between multiple groups. Statistical significance was defined as p<0.05.
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. Supplementary file 1. 134 de novo mutated genes from CHD study participants with corresponding
Drosophila homologs showing conservation score (Hu et al., 2011), function (from Flybase) and mor-
tality index (determined by crossing homozygous UAS-RNAi transgenic flies with flies bearing a
4XHand-Gal4 driver balanced over CyO, progeny flies that emerge as adults with curly wings (CyO,
no transgene expression) vs. straight wings (4XHand-Gal4 driven UAS-RNAi transgene expression in
cardioblasts) are recorded and the lethal rate attributable to RNAi heart expression is calculated as
(Curly – Straight / Curly) X 100 = % Mortality). Patient identification number, human gene, mutation
type and category (DH, damaging mutation in gene with homolog expression high in embryonic day
14.5 mouse heart (emh); CH, mutation in phylogenetically conserved region of gene with homolog
expression high in emh; NH, mutation in phylogenetically nonconserved region of gene with homo-
log expression high in emh; DL, damaging mutation in gene with homolog expression low in emh;
CL, mutation in phylogenetically conserved region of gene with homolog expression low in emh; NL,
mutation in phylogenetically nonconserved region of gene with homolog expression low in emh) are
from (Zaidi et al., 2013).
DOI: 10.7554/eLife.22617.011
. Supplementary file 2. Drosophila lines used to silence expression of genes. Flies were obtained
from either the Bloomington Drosophila Stock Center (BDSC) or the Vienna Drosophila Resource
Center (VDRC). Individual fly lines are identified by source ID numbers. Both the human genes and
their corresponding Drosophila homologs are listed. Each line carries an inhibitory RNA transgene
designed to silence the indicated Drosophila gene, cloned downstream of a UAS DNA element. The
RNAi transgene is only expressed in cells producing the yeast Gal4 transcription factor.
DOI: 10.7554/eLife.22617.012
. Supplementary file 3. Gene specific PCR primers.
DOI: 10.7554/eLife.22617.013
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